Looking into the "Garden of the Hesperides": new drugs for hepatocellular carcinoma

Minerva Chir. 2015 Apr;70(2):119-29. Epub 2015 Jan 23.

Abstract

Advanced hepatocellular carcinoma remains an entity that is hard to approach therapeutically and has shown disappointing results in terms of survival. For many years, the only accepted option for this setting was the use of a multikinase inhibitor, sorafenib. Nevertheless, through the years, a deeper knowledge has arisen about how pathogenic pathways correlate with hepatocellular carcinoma. In this review, we provide an update of the most recent data regarding new agents under investigation and new possible targets for future treatments.

Trial registration: ClinicalTrials.gov NCT02325739.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / therapy
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy / methods
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / therapy
  • Mechanistic Target of Rapamycin Complex 1
  • Metaphor
  • Multiprotein Complexes / pharmacology
  • Multiprotein Complexes / therapeutic use*
  • Prognosis
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / pharmacology
  • TOR Serine-Threonine Kinases / therapeutic use*
  • Treatment Outcome
  • Wnt Signaling Pathway / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Multiprotein Complexes
  • Proto-Oncogene Proteins c-met
  • Mechanistic Target of Rapamycin Complex 1
  • TOR Serine-Threonine Kinases

Associated data

  • ClinicalTrials.gov/NCT02325739